Dr. Öğr. Üyesi Yasin Sezgin

1. Glasgow prognostic score as a predictor of adjuvant nivolumab efficacy in esophageal squamous cell carcinoma

Kara M., Ebinç S., Sezgin Y., Ürün M., Aldemir M. N.

BMC Gastroenterology , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

2. Predictive value of kynurenine pathway metabolites in patients with diabetic kidney disease

Erdem M., Alp H. H., Düzen Oflas N., Aydemir O., Aydin İ., Karaca C., et al.

Acta Diabetologica , cilt.63, sa.10, ss.1697-1706, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

3. The Prognostic Value of the Advanced Lung Cancer Inflammation Index on Disease-Free Survival in Patients with Gastric Cancer Receiving Neoadjuvant Chemotherapy

Kara M., Ürün M., Ebinç S., Sezgin Y., Yılmaz Ürün Y., Aldemir M. N.

Journal of Clinical Medicine , cilt.15, sa.17, 2026 (SCI-Expanded, Scopus)

4. Association of Metastatic Lymph Node Count and Primary Tumor Size with Disease-Free Survival in Stage II–III Gastric Cancer: A Retrospective Cohort Study

Kanatsız E., Sezgin Y., Yılmaz Ürün Y.

Medicina (Lithuania) , cilt.62, sa.8, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

5. Effects of Cisplatin on the Renin-Angiotensin-Aldosterone System and the Regulatory Role of Dexketoprofen Trometamol: An Experimental Study in Rats

Akman N., Sezgin Y., Başbuğan Y., Kömüroğlü A. U., Bazancir N.

Eastern Journal of Medicine , cilt.31, sa.3, ss.419-426, 2026 (Scopus, TRDizin)

6. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

Sezgin Y., Karhan O., Aldemir M. N., Ürün M., Erçek B. M., Urakcı Z., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

7. Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study

Karhan O., İleri S., Urakçl Z., Arvas H., Klllç D. K., Sezgin Y., et al.

Oncology (Switzerland) , cilt.103, sa.6, ss.498-507, 2025 (SCI-Expanded, Scopus)

8. The Role of Bıomarkers In Predıctıng Neoadjuvant Treatment Response In Gastrıc Cancer

Sezgin Y., Ürün M.

Eastern Journal of Medicine , cilt.30, sa.2, ss.245-255, 2025 (Scopus, TRDizin)

9. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

Karhan O., İleri S., Urakçı Z., Sezgin Y., Yıldırım Ü., Ünlü B., et al.

Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded, Scopus)

10. Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer: A Retrospective Analysis of 96 Patients

Ürün M., Güner G., Sezgin Y., Uysal E., SAKİN A., Kilickap S.

Medical Science Monitor , cilt.30, 2024 (SCI-Expanded, Scopus)

11. Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience

Sezgin Y., Karhan O., Ileri S., Ebinc S., Tunc S., Urakci Z.

Journal of the College of Physicians and Surgeons Pakistan , cilt.34, sa.8, ss.904-909, 2024 (SCI-Expanded, Scopus)

12. Testis Kanserinde Prognostik Faktörler

Sezgin Y., Karhan O., Biçer A., İleri S., Yerlikaya H., Tunç S., et al.

Turkish Journal of Clinics and Laboratory , cilt.15, sa.2, ss.176-181, 2024 (TRDizin)

13. Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer

Karhan O., Sezgin Y., Ileri S., Tunc S.

Nigerian journal of clinical practice , cilt.27, sa.6, ss.800-803, 2024 (SCI-Expanded, Scopus)

14. Comparison of the Efficacy of Dual Chemotherapy Regimens in Second-Line Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Guner G., Sezgin Y.

Eurasian Journal of Medical Investigation , cilt.8, sa.1, ss.48-53, 2024 (TRDizin)

15. Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats

Sezgin Y., Bora E. S., Arda D. B., UYANIKGİL Y., Erbaş O.

Acta cirurgica brasileira , cilt.39, 2024 (SCI-Expanded, Scopus)

16. Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer

Ürün M., Güner G., Sezgin Y., SAKİN A., Kılıçkap S.

Medical Science Monitor , cilt.30, 2024 (SCI-Expanded, Scopus)

17. The impact of timing adjuvant therapy on disease-free survival among patients with stage iib-iiia non-small cell lung cancer receiving platinum- based treatment

ÜRÜN M., SEZGİN Y., UYSAL E.

Turkish Journal of Clinics and Laboratory , cilt.14, sa.3, ss.639-644, 2023 (TRDizin)

18. Comparison of the Efficacy of FOLFIRI and Paclitaxel Chemotherapy Regimens in the Second Line Treatment of Metastatic Gastric Cancer

ÜRÜN M., GÜNER G., SEZGİN Y., YILMAZ ÜRÜN Y., SAKİN A.

Van Yuzuncu Yil University , cilt.16, sa.2, ss.176-182, 2023 (Hakemli Dergi)

19. ADDITIONAL COST OF OVERWEIGHT IN MEDICATION OF CANCER PATIENTS

ÜRÜN M., SEZGİN Y., YILMAZ ÜRÜN Y., UÇAN A., GÜRCÜ S., TUĞRUL F.

Eskisehir Medical Journal, Eskisehir City Hospital , cilt.4, sa.2, ss.107-110, 2023 (Hakemli Dergi)

20. Are Syrian refugee breast cancer patients diagnosed at advanced stage and do they have treatment delays?

Karhan O., Secmeler Ş., Sezgin Y., Ileri S., Yerlikaya H.

Future Oncology , cilt.19, sa.14, ss.983-989, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

21. The Prediction of Overall Survival With The Use of The Sarculator In Operated Soft Tissue Sarcoma of The Extremities: Monocentre Experience

Sezgin Y., Karhan O.

Eastern Journal of Medicine , cilt.28, sa.4, ss.804-809, 2023 (Scopus, TRDizin)

22. Chemotherapy Efficacy and Tolerability in Metastatic Gastric Cancer Patients Aged 75 Years and Older

SEZGİN Y., YILMAZ ÜRÜN Y.

Eurasian Journal of Medical Investigation , cilt.7, sa.4, ss.487-493, 2023 (TRDizin)

23. Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy

Ebinç S., Oruç Z., Sezgin Y., Karhan O. u., Bilen E., Yerlikaya H., et al.

Future Oncology , cilt.18, sa.30, ss.3399-3408, 2022 (SCI-Expanded, Scopus)

24. The Relatıonshıp Between Pet Ct And Tumor Features In Patıents Wıth Breast Cancer

SEZGİN Y., KARHAN O., İLERİ S., EBİNÇ S., BİLEN E., ÜRÜN M., et al.

Van Tıp Dergisi , cilt.29, 2022 (TRDizin)

25. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort

Karaağaç M., Sezgin Y., Eryılmaz M. K., Araz M., Kaplan M. A., Artaç M.

Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1657-1666, 2020 (SCI-Expanded, Scopus)